中心凹下脉络膜厚度作为渗出性年龄相关性黄斑变性的预后因素
本回顾性病例系列纳入62例连续初治渗出性AMD患者,随访1年,按treat-and-extend或PRN方案接受抗VEGF治疗。基线中心凹下脉络膜厚度(SFCT)平均187 µm,基线SFCT较厚与1年内玻璃体腔注射次数更多显著相关(p=0.004),但与基线及1年视力无关联。
要点
- 基线SFCT较厚与1年内抗VEGF注射次数更多显著相关(p=0.004)。
- 基线SFCT与基线视网膜下液、视网膜内液或视网膜下高反射物质均无相关性。
- 基线SFCT与基线及1年视力均无关联(p=0.7和p=0.2)。
核心结论
- 初治渗出性AMD患者的SFCT可能有助于判断治疗负担,中心凹下脉络膜较厚者可能需要更多玻璃体腔注射。
研究设计与样本
- 回顾性病例系列,纳入62例连续初治渗出性AMD患者,随访1年,采用treat-and-extend或PRN抗VEGF方案。
- 使用Cirrus HD-OCT在基线、3、6和12个月测量中心凹中心及鼻侧、颞侧500 µm共三个位置的SFCT。
主要发现
- 基线平均SFCT为187 µm(范围70-361 µm),1年时173 µm,与3个月175 µm和基线188 µm相比呈下降趋势(p=0.2)。
- 基线SFCT与基线视网膜下液(p=0.2)、视网膜内液(p=0.6)或视网膜下高反射物质(p=0.4)均无相关性。
- 1年平均注射次数为6.6次(范围2-12次),基线SFCT较高与1年玻璃体腔注射次数更多显著相关(p=0.004)。
- 基线SFCT高于均值1个标准差以上的眼所需注射次数比其他眼多50%。
- 基线SFCT与基线及1年视力均无关联(p=0.7和p=0.2)。
临床怎么用
- 对初治渗出性AMD患者,可测量基线SFCT以辅助预估1年内抗VEGF治疗负担。
- 中心凹下脉络膜较厚的患者可能需更密切随访和更多注射,但需结合其他因素综合判断。
局限性
- 本研究为回顾性病例系列,样本量62例,随访1年,结论需更大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the relationship between subfoveal choroidal thickness (SFCT), visual acuity (VA), optical coherence tomography (OCT) features and total anti-vascular endothelial growth factor (VEGF) treatments to determine whether SFCT serves as a prognostic factor in age-related macular degeneration (AMD). METHODS: This is a retrospective case series of 62 consecutive treatment-naive patients with exudative AMD followed for 1 year and treated with treat-and-extend or pro re nata anti-VEGF protocols. SFCT was measured at three locations using Cirrus HD-OCT (the foveal centre and 500 um nasal and temporal to the fovea) at presentation, 3, 6 and 12 months. Demographic characteristics, OCT imaging biomarkers and VA were recorded. RESULTS: Mean SFCT at baseline was 187 µm (range: 70-361 µm). There was a trend of decreasing SFCT at 1 year (173 µm) compared with 3 months (175 µm) and baseline (188 µm) (p=0.2). There was no correlation between baseline SFCT and presence of subretinal fluid (p=0.2), intraretinal fluid (p=0.6) or subretinal hyper-reflective material (p=0.4) at baseline. The mean number of injections at 1 year was 6.6 (range: 2-12). Increased SFCT at baseline showed statistically significant correlation with a higher number of intravitreal injections at 1 year (p=0.004). Eyes with SFCT>1 SD above the mean required 50% more injections compared with others. There was no association between SFCT on presentation with baseline and 1 year VA (p=0.7 and p=0.2). CONCLUSIONS: SFCT in naïve patients with exudative AMD may be an important prognostic tool in determining treatment burden. Patients with thicker subfoveal choroid may require increased intravitreal injections.
引用
- Kumar JB, Wai KM, Ehlers JP, et al. Subfoveal choroidal thickness as a prognostic factor in exudative age-related macular degeneration. Br J Ophthalmol. 2018. PMID: 30150279. doi:10.1136/bjophthalmol-2018-312625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。